| 38.485 0.975 (2.6%) | 07-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 47.07 | 1-year : | 54.97 |
| Resists | First : | 40.29 | Second : | 47.07 |
| Pivot price | 36.57  |
|||
| Supports | First : | 36.01 |
Second : | 33.36 |
| MAs | MA(5) : | 36.5 |
MA(20) : | 37.14 |
| MA(100) : | 33.01 |
MA(250) : | 28.47 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 62.1 |
D(3) : | 45.6 |
| RSI | RSI(14): 63.8 |
|||
| 52-week | High : | 40.29 | Low : | 19.71 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CLDX ] has closed below upper band by 18.1%. Bollinger Bands are 11.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 38.64 - 38.8 | 38.8 - 38.95 |
| Low: | 36.85 - 37.02 | 37.02 - 37.18 |
| Close: | 38.21 - 38.48 | 38.48 - 38.74 |
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Wed, 29 Jul 2026
Celldex Therapeutics Inc (CLDX) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
Tue, 28 Jul 2026
Celldex Therapeutics Inc (CLDX) Institutional Confidence - tradingkey.com
Tue, 28 Jul 2026
CLDX|Celldex Therapeutics Inc|Price:37.520|Chg%:+1.940 - tradingkey.com
Sun, 26 Jul 2026
Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts (NASDAQ:CLDX) - Seeking Alpha
Sat, 25 Jul 2026
Are Phase 2 Prurigo Nodularis Data And CFO Transition Altering The Investment Case For Celldex (CLDX)? - Sahm
Fri, 24 Jul 2026
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 7.246e+007 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 7,300 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.057e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -562 % |
| Return on Assets (ttm) | 900 % |
| Return on Equity (ttm) | -30.9 % |
| Qtrly Rev. Growth | 865000 % |
| Gross Profit (p.s.) | -108.67 |
| Sales Per Share | -54.38 |
| EBITDA (p.s.) | -2.94e+008 |
| Qtrly Earnings Growth | -4.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -222 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.71 |
| Price to Cash Flow | 5.05 |
| Dividend | 0 |
| Forward Dividend | 7.66e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|